Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.195
-0.005 (-0.42%)
Dec 30, 2024, 11:42 AM EST - Market open
Actinium Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Other Revenue | 0.08 | 0.08 | 1.03 | 1.14 | - | - | |
| Revenue | 0.08 | 0.08 | 1.03 | 1.14 | - | - | |
| Revenue Growth (YoY) | - | -92.14% | -9.97% | - | - | - | |
| Gross Profit | 0.08 | 0.08 | 1.03 | 1.14 | - | - | |
| Selling, General & Admin | 11.69 | 13.33 | 12 | 8.08 | 6.31 | 5.52 | |
| Research & Development | 33.35 | 38.67 | 23.14 | 18.03 | 16.09 | 16.55 | |
| Operating Expenses | 45.04 | 52 | 35.13 | 26.11 | 22.39 | 22.07 | |
| Operating Income | -44.96 | -51.92 | -34.1 | -24.96 | -22.39 | -22.07 | |
| Interest & Investment Income | 4.04 | 3.1 | 1.09 | 0.19 | 0.18 | 0.17 | |
| EBT Excluding Unusual Items | -40.92 | -48.82 | -33.02 | -24.77 | -22.22 | -21.9 | |
| Pretax Income | -40.92 | -48.82 | -33.02 | -24.77 | -22.22 | -21.9 | |
| Net Income | -40.92 | -48.82 | -33.02 | -24.77 | -22.22 | -21.9 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 0 | 0 | |
| Net Income to Common | -40.92 | -48.82 | -33.02 | -24.77 | -22.22 | -21.9 | |
| Shares Outstanding (Basic) | 29 | 27 | 24 | 21 | 12 | 5 | |
| Shares Outstanding (Diluted) | 29 | 27 | 24 | 21 | 12 | 5 | |
| Shares Change (YoY) | 11.51% | 10.20% | 17.37% | 69.51% | 143.87% | 40.77% | |
| EPS (Basic) | -1.40 | -1.83 | -1.37 | -1.20 | -1.83 | -4.40 | |
| EPS (Diluted) | -1.40 | -1.83 | -1.37 | -1.20 | -1.83 | -4.40 | |
| Free Cash Flow | -34.82 | -47.49 | 8.28 | -21 | -21.87 | -21.53 | |
| Free Cash Flow Per Share | -1.20 | -1.78 | 0.34 | -1.02 | -1.80 | -4.33 | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - | |
| Operating Margin | -55504.94% | -64098.77% | -3311.07% | -2182.17% | - | - | |
| Profit Margin | -50512.35% | -60269.14% | -3205.53% | -2165.56% | - | - | |
| Free Cash Flow Margin | -42990.12% | -58627.16% | 803.69% | -1835.58% | - | - | |
| EBITDA | -44.73 | -51.71 | -33.9 | -24.78 | -22.26 | -21.94 | |
| D&A For EBITDA | 0.23 | 0.21 | 0.21 | 0.19 | 0.14 | 0.14 | |
| EBIT | -44.96 | -51.92 | -34.1 | -24.96 | -22.39 | -22.07 | |
| Revenue as Reported | 0.08 | 0.08 | 1.03 | 1.14 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.